Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL813789 | 0.92 | CA2 (0.56) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL1004665 | 0.92 | CA2 (0.56) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL2806008 | 0.89 | CA2 (0.59) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL31396735 | 0.89 | CA2 (0.59) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL187925 | 0.89 | CA2 (0.59) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL80648 | 0.89 | CA2 (0.59) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL9960580 | 0.85 | CA2 (0.63) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL93763 | 0.85 | CA2 (0.63) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL1894893 | 0.83 | CA2 (0.53) | CA2CA1MAPK1ATMGAA | |
| SCHEMBL18334306 | 0.82 | CA2 (0.59) | CA2CA1MAPK1ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210921-A1 | Method for Giving Warmth to Skin | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | claimed |
| EP-1752164-B1 | PERCUTANEOUS PHARMACEUTICAL PREPARATION FOR EXTERNAL USE CONTAINING NONSTEROIDAL ANTIINFLAMMATORY ANALGESIC | HISAMITSU PHARMACEUTICAL CO (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20130210921-A1 | Method for Giving Warmth to Skin | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20110027326-A1 | External Composition for Skin | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2269652-A1 | COMPOSITION FOR EXTERNAL APPLICATION TO SKIN | Rohto Pharmaceutical Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20070280980-A1 | Percutaneous Pharmaceutical Preparation for External Use Containing Nonsteroidal Antiinflammatory Analgesic | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070275022-A1 | Cosmetic Hair Preparation | LION CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1752164-A1 | PERCUTANEOUS PHARMACEUTICAL PREPARATION FOR EXTERNAL USE CONTAINING NONSTEROIDAL ANTIINFLAMMATORY ANALGESIC | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275022-A1 | Cosmetic Hair Preparation | CUTA, H1-10, PUF60 | CA2 669/4885CA1 374/4885MAPK1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.